Discovery of Clinically Approved Agents That Promote Suppression of CFTR Nonsense Mutations.

CONCLUSIONS: Clinically approved drugs identified as potential readthrough agents, in combination with ivacaftor, may induce nonsense suppression to restore therapeutic levels of CFTR function. One or more agents may be suitable to advance to human testing.
PMID: 27104944 [PubMed - as supplied by publisher]

Source: American Journal of Respiratory and Critical Care Medicine - April 21, 2016 Category: Respiratory Medicine Authors: Mutyam V, Du M, Xue X, Keeling KM, White EL, Bostwick JR, Rasmussen L, Liu B, Mazur M, Hong JS, Falk Libby E, Liang F, Shang H, Mense M, Suto MJ, Bedwell DM, Rowe SM Tags: Am J Respir Crit Care Med Source Type: research